Sareum discovers anticancer compound, plans clinical development

By Elaine Rigoli

Tampa, Fla., Aug. 31 - Sareum Holdings plc said Thursday that substantial progress - including the discovery of novel compound series that show efficacy in cancer cell models - has been made in its collaboration with The Institute of Cancer Research and Cancer Research Technology Ltd., an oncology-focused development company.

The compound series targets a specific enzyme in a key biochemical pathway, responsible for preventing the effectiveness of traditional cancer therapeutics such as chemotherapy, according to a news release by the Cambridge, U.K.-based drug-discovery company.

In the collaboration, the team is now working to optimize a series of compounds to provide a validated candidate to take forward into clinical development.

The new cancer therapeutics developed will potentially allow effective treatment of tumors that do not respond to current treatments as well as lowering the dose required of existing therapies to reduce adverse side effects.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.